BRPI0417990A - uso de polimorfismos de receptor fc como diagnósticos para estratégias de tratamento para distúrbios de resposta imune - Google Patents

uso de polimorfismos de receptor fc como diagnósticos para estratégias de tratamento para distúrbios de resposta imune

Info

Publication number
BRPI0417990A
BRPI0417990A BRPI0417990-0A BRPI0417990A BRPI0417990A BR PI0417990 A BRPI0417990 A BR PI0417990A BR PI0417990 A BRPI0417990 A BR PI0417990A BR PI0417990 A BRPI0417990 A BR PI0417990A
Authority
BR
Brazil
Prior art keywords
immunotherapy
diagnostics
treatment
polymorphisms
immune response
Prior art date
Application number
BRPI0417990-0A
Other languages
English (en)
Inventor
Susan E Wilson
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of BRPI0417990A publication Critical patent/BRPI0417990A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE POLIMORFISMOS DE RECEPTOR FC COMO DIAGNóSTICOS PARA ESTRATéGIAS DE TRATAMENTO PARA DISTúRBIOS DE RESPOSTA IMUNE". São fornecidos métodos para o uso de polimorfismos de receptor Fc gama (FcγR) como um diagnóstico para intervenção com imunoterapia com interleucina-2 (IL-2). Os métodos compreendem a detecção do padrão alélico de um gene FcγRIIIA ou gene FcγRIIA de um indivíduo, e determinar se o padrão alélico é preditivo de uma resposta terapêutica positiva à imunoterapia com IL-2. A presença do genótipo homozigótico FcγRIIIA 158F/F, e/ou a presença de uma ou ambas cópias do alelo FcγRHIIA 48L, e/ou a presença de uma ou ambas cópias do alelo FcγRIIA 131R é preditivo de uma resposta terapêutica positiva à imunoterapia com IL-2, e portanto indicativa de intervenção médica com imunoterapia com IL-2 para o tratamento de um distúrbio imune. O método diagnóstico tem uso na identificação daqueles indivíduos cuja função imune pode ser melhorada por tratamento com imunoterapia Com IL-2, particularmente para indivíduos com câncer.
BRPI0417990-0A 2003-12-22 2004-12-22 uso de polimorfismos de receptor fc como diagnósticos para estratégias de tratamento para distúrbios de resposta imune BRPI0417990A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53183203P 2003-12-22 2003-12-22
US55175904P 2004-03-11 2004-03-11
US55226004P 2004-03-11 2004-03-11
US57642904P 2004-06-03 2004-06-03
PCT/US2004/043316 WO2005062929A2 (en) 2003-12-22 2004-12-22 Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders

Publications (1)

Publication Number Publication Date
BRPI0417990A true BRPI0417990A (pt) 2007-04-27

Family

ID=34743873

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417990-0A BRPI0417990A (pt) 2003-12-22 2004-12-22 uso de polimorfismos de receptor fc como diagnósticos para estratégias de tratamento para distúrbios de resposta imune

Country Status (10)

Country Link
US (1) US20060165653A1 (pt)
EP (1) EP1709196A4 (pt)
JP (1) JP2007515185A (pt)
KR (1) KR20070001931A (pt)
AU (1) AU2004308452A1 (pt)
BR (1) BRPI0417990A (pt)
CA (1) CA2550998A1 (pt)
IL (1) IL176458A0 (pt)
MX (1) MXPA06007236A (pt)
WO (1) WO2005062929A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005091956A2 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
EP1960549A4 (en) * 2005-11-30 2010-01-13 Univ Southern California Fc-GAMMA POLYMORPHISMS FOR PREDICTING A DISEASE AND THE RESULTS OF TREATMENT
CA2650730A1 (en) * 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
CA2675352A1 (en) 2007-01-18 2008-07-24 University Of Southern California Genetic markers for predicting responsiveness to combination therapy
US20120039871A1 (en) * 2007-11-08 2012-02-16 Pikamab, Inc. Methods and compositions for antibody therapy
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2944199C (en) * 2014-03-28 2023-08-15 Regents Of The University Of Minnesota Polypeptides, cells, and methods involving engineered cd16
US20170045528A1 (en) * 2014-04-25 2017-02-16 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
SG11201909949XA (en) 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
CN111373261A (zh) * 2017-11-20 2020-07-03 尤利乌斯·马克西米利安维尔茨堡大学 Cd19 cart细胞可清除表达极低水平cd19的骨髓瘤细胞
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
EP4107187A1 (en) 2020-02-21 2022-12-28 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228180B1 (hu) * 1998-08-11 2013-01-28 Biogen Idec Inc Anti-CD20-ellenanyag alkalmazása B-sejtes limfómák kombinációs terápiájára
CA2469045A1 (en) * 2001-12-07 2003-06-19 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma

Also Published As

Publication number Publication date
EP1709196A4 (en) 2008-10-29
WO2005062929A3 (en) 2006-07-20
MXPA06007236A (es) 2006-08-31
IL176458A0 (en) 2006-10-05
KR20070001931A (ko) 2007-01-04
CA2550998A1 (en) 2005-07-14
JP2007515185A (ja) 2007-06-14
WO2005062929A2 (en) 2005-07-14
US20060165653A1 (en) 2006-07-27
EP1709196A2 (en) 2006-10-11
AU2004308452A1 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
BRPI0417990A (pt) uso de polimorfismos de receptor fc como diagnósticos para estratégias de tratamento para distúrbios de resposta imune
Kyogoku et al. Fcγ receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility
Mata et al. Lrrk2 pathogenic substitutions in Parkinson's disease
Lawson et al. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene
Nezos et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome
Ben-Yosef et al. A mutation of PCDH15 among Ashkenazi Jews with the type 1 Usher syndrome
Kalachikov et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features
Sander et al. Association analysis of sequence variants of the GABAAα6, β2, and γ2 gene cluster and alcohol dependence
Cox et al. Association of atopic dermatitis to the beta subunit of the high affinity immunoglobulin E receptor
Brkanac et al. Autosomal dominant sensory/motor neuropathy with Ataxia (SMNA): Linkage to chromosome 7q22‐q32
Julià et al. The role of fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis: a pharmacogenetic study
Klein et al. Clinical testing for the nevoid basal cell carcinoma syndrome in a DNA diagnostic laboratory
Isidoro-García et al. Interleukin-4 (IL4) and Interleukin-4 receptor (IL4RA) polymorphisms in asthma: a case control study
WO2004020968A3 (en) Mutations in nod2 are associated with fibrostenosing disease in patients with crohn’s disease
Ramoz et al. Lack of evidence for association of the serotonin transporter gene SLC6A4 with autism
Limosin et al. Association Between Dopamine Receptor D1 Gene Dde I polymorphism and Sensation Seeking in Alcohol‐Dependent Men
Na et al. Proinflammatory gene polymorphisms are potentially associated with Korean non-Sjogren dry eye patients
Koh et al. Association study of semaphorin 7a (sema7a) polymorphisms with bone mineral density and fracture risk in postmenopausal Korean women
Lee et al. Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer's disease in adults with Down syndrome
Kuo et al. FCGR2A promoter methylation and risks for intravenous immunoglobulin treatment responses in Kawasaki disease
Eriksson et al. The 434 (G> C) polymorphism within the coding sequence of Eosinophil Cationic Protein (ECP) correlates with the natural course of Schistosoma mansoni infection
Liu et al. Haplotypes of the D-amino acid oxidase gene are significantly associated with schizophrenia and its neurocognitive deficits
Kantarci Genetics and natural history of multiple sclerosis
Jurkiewicz et al. Four novel RSK2 mutations in females with Coffin–Lowry syndrome
Pae et al. Tumor necrosis factor‐α gene polymorphism at position− 308 and schizophrenia in the Korean population

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US)

Free format text: ALTERADO DE: CHIRON CORPORATION

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.